nach oben

Erschienen in:

01.06.2018 | Brief Article

Improved Debulking of Peritoneal Tumor Implants by Near-Infrared Fluorescent Nanobody Image Guidance in an Experimental Mouse Model

verfasst von: Pieterjan Debie, Marian Vanhoeij, Natalie Poortmans, Janik Puttemans, Kris Gillis, Nick Devoogdt, Tony Lahoutte, Sophie Hernot

Erschienen in: Molecular Imaging and Biology | Ausgabe 3/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Debulking followed by combination chemotherapy is currently regarded as the most effective treatment for advanced ovarian cancer. Prognosis depends drastically on the degree of debulking. Accordingly, near-infrared (NIR) fluorescence imaging has been proposed to revolutionize cancer surgery by acting as a sensitive, specific, and real-time tool enabling visualization of cancer lesions. We have previously developed a NIR-labeled nanobody that allows fast, specific, and high-contrast imaging of HER2-positive tumors. In this study, we applied this tracer during fluorescence-guided surgery in a mouse model and investigated the effect on surgical efficiency.

Procedures

0.5 × 10⁶ SKOV3.IP1-Luc+ cells were inoculated intraperitoneally in athymic mice and were allowed to grow for 30 days. Two nanomoles of IRDye800CW-anti-HER2 nanobody was injected intravenously. After 1h30, mice were killed, randomized in two groups, and subjected to surgery. In the first animal group (n = 7), lesions were removed by a conventional surgical protocol, followed by excision of remaining fluorescent tissue using a NIR camera. The second group of mice (n = 6) underwent directly fluorescence-guided surgery. Bioluminescence imaging was performed before and after surgery. Resected tissue was categorized as visualized during conventional surgery or not, fluorescent or not, and bioluminescent positive or negative.

Results

Fluorescence imaging allowed clear visualization of tumor nodules within the abdomen, up to submillimeter-sized lesions. Fluorescence guidance resulted in significantly reduced residual tumor as compared to conventional surgery. Moreover, sensitivity increased from 59.3 to 99.0 %, and the percentage of false positive lesions detected decreased from 19.6 to 7.1 %.

Conclusions

This study demonstrates the advantage of intraoperative fluorescence imaging using nanobody-based tracers on the efficiency of debulking surgery.

Nur mit Berechtigung zugänglich

Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J et al (2013) Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 49:1374–1403CrossRefPubMed

Bray F, Ren JS, Masuyer E, Ferlay J (2013) Global estimates of cancer prevalence for 27 sites in the adult population in 2008. Int J Cancer 132:1133–1145CrossRefPubMed

Prat J (2014) Staging classification for cancer of the ovary, fallopian tube, and peritoneum. Int J Gynecol Obstet 124:1–5CrossRef

Jayson GC, Kohn EC, Kitchener HC, Ledermann JA (2014) Ovarian cancer. Lancet 384:1376–1388CrossRefPubMed

Schorge JO, McCann C, Del Carmen MG (2010) Surgical debulking of ovarian cancer: what difference does it make? Rev Obstet Gynecol 3:111–117PubMedPubMedCentral

Pereira A, Pérez-Medina T, Magrina JF et al (2016) The impact of debulking surgery in patients with node-positive epithelial ovarian cancer: analysis of prognostic factors related to overall survival and progression-free survival after an extended long-term follow-up period. Surg Oncol 25:49–59CrossRefPubMed

Lim MC, Seo S-S, Kang S et al (2012) Intraoperative image-guided surgery for ovarian cancer. Quant Imaging Med Surg 2:114–117PubMedPubMedCentral

Wallace S, Kumar A, Mc M et al (2017) Efforts at maximal cytoreduction improve survival in ovarian cancer patients, even when complete gross resection is not feasible. Gynecol Oncol 145:21–26CrossRefPubMed

Rafii A, Stoeckle E, Jean-Laurent M et al (2012) Multi-center evaluation of post-operative morbidity and mortality after optimal cytoreductive surgery for advanced ovarian cancer. PLoS One. https://doi.org/10.1371/journal.pone.0039415

10.

Zhang RR, Schroeder AB, Grudzinski JJ et al (2017) Beyond the margins: real-time detection of cancer using targeted fluorophores. Nat Rev Clin Oncol. https://doi.org/10.1038/nrclinonc.2016.212

11.

van Dam GM, Themelis G, Crane LMA et al (2011) Intraoperative tumor-specific fluorescence imaging in ovarian cancer by folate receptor-α targeting: first in-human results. Nat Med 17:1315–1319CrossRefPubMed

12.

Hoogstins CES, Tummers QRJG, Gaarenstroom KN et al (2016) A novel tumor-specific agent for intraoperative near-infrared fluorescence imaging: a translational study in healthy volunteers and patients with ovarian cancer. Clin Cancer Res 22:2929–2938CrossRefPubMed

13.

Tipirneni KE, Warram JM, Moore LS et al (2017) Oncologic procedures amenable to fluorescence-guided surgery. Ann Surg 266:36–47CrossRefPubMed

14.

Rosenthal EL, Moore LS, Tipirneni K et al (2017) Sensitivity and specificity of cetuximab-IRDye800CW to identify regional metastatic disease in head and neck cancer. Clin Cancer Res 23:4744–4752CrossRefPubMed

15.

Lamberts LE, Koch M, de Jong JS, et al (2016) Tumor-specific uptake of fluorescent bevacizumab-IRDye800CW microdosing in patients with primary breast cancer: a phase I feasibility study. Clin Cancer Res

16.

Bannas P, Lenz A, Kunick V et al (2015) Molecular imaging of tumors with nanobodies and antibodies: timing and dosage are crucial factors for improved in vivo detection. Contrast Media Mol Imaging. https://doi.org/10.1002/cmmi.1637

17.

De Vos J, Devoogdt N, Lahoutte T, Muyldermans S (2013) Camelid single-domain antibody-fragment engineering for (pre)clinical in vivo molecular imaging applications: adjusting the bullet to its target. Expert Opin Biol Ther 13:1149–1160CrossRefPubMed

18.

Hamers-Casterman C, Atarhouch T, Muyldermans S et al (1993) Naturally occurring antibodies devoid of light chains. Nature 363:446–448CrossRefPubMed

19.

Kijanka M, Warnders F-J, El Khattabi M et al (2013) Rapid optical imaging of human breast tumour xenografts using anti-HER2 VHHs site-directly conjugated to IRDye 800CW for image-guided surgery. Eur J Nucl Med Mol Imaging 40:1718–1729CrossRefPubMed

20.

Debie P, Van Quathem J, Hansen I et al (2017) Effect of dye and conjugation chemistry on the biodistribution profile of near-infrared-labeled nanobodies as tracers for image-guided surgery. Mol Pharm 14:1145–1153CrossRefPubMed

21.

Broisat A, Hernot S, Toczek J et al (2012) Nanobodies targeting mouse/human VCAM1 for the nuclear imaging of atherosclerotic lesions. Circ Res 110:927–937CrossRefPubMedPubMedCentral

22.

Keyaerts M, Xavier C, Heemskerk J et al (2016) Phase I study of 68Ga-HER2-nanobody for PET/CT assessment of HER2 expression in breast carcinoma. J Nucl Med 57:27–33CrossRefPubMed

23.

Blykers A, Schoonooghe S, Xavier C et al (2015) PET imaging of macrophage mannose receptor-expressing macrophages in tumor stroma using 18F-radiolabeled camelid single-domain antibody fragments. J Nucl Med 56:1265–1271CrossRefPubMed

24.

Chakravarty R, Goel S, Cai W (2014) Nanobody: the “magic bullet” for molecular imaging? Theranostics 4:386–398CrossRefPubMedPubMedCentral

25.

Steeland S, Vandenbroucke RE, Libert C (2016) Nanobodies as therapeutics: big opportunities for small antibodies. Drug Discov Today 21:1076–1113CrossRefPubMed

26.

De Vlieghere E, Carlier C, Ceelen W et al (2016) Data on in vivo selection of SK-OV-3 Luc ovarian cancer cells and intraperitoneal tumor formation with low inoculation numbers. Data Brief 6:542–549CrossRefPubMedPubMedCentral

27.

Keyaerts M, Verschueren J, Bos TJ et al (2008) Dynamic bioluminescence imaging for quantitative tumour burden assessment using IV or IP administration of d-luciferin: effect on intensity, time kinetics and repeatability of photon emission. Eur J Nucl Med Mol Imaging 35:999–1007CrossRefPubMed

28.

Vahrmeijer AL, Hutteman M, van der Vorst JR et al (2013) Image-guided cancer surgery using near-infrared fluorescence. Nat Rev Clin Oncol 10:507–518CrossRefPubMedPubMedCentral

29.

Coccolini F, Gheza F, Lotti M et al (2013) Peritoneal carcinomatosis. World J Gastroenterol 19:6979–6994CrossRefPubMedPubMedCentral

30.

Harlaar NJ, Kelder W, Sarantopoulos A et al (2013) Real-time near infrared fluorescence (NIRF) intra-operative imaging in ovarian cancer using an αvβ3-integrin targeted agent. Gynecol Oncol 128:590–595CrossRefPubMed

31.

Handgraaf HJM, Boonstra MC, Prevoo HAJM et al (2017) Real-time near-infrared fluorescence imaging using cRGD-ZW800-1 for intraoperative visualization of multiple cancer types. Oncotarget 8:21054–21066CrossRefPubMed

32.

Day KE, Beck LN, Deep NL et al (2013) Fluorescently labeled therapeutic antibodies for detection of microscopic melanoma. Laryngoscope 123:2681–2689CrossRefPubMed

33.

Christensen A, Juhl K, Persson M et al (2017) uPAR-targeted optical near-infrared (NIR) fluorescence imaging and PET for image-guided surgery in head and neck cancer: proof-of-concept in orthotopic xenograft model. Oncotarget 8:20519–20520CrossRef

34.

Metildi CA, Kaushal S, Snyder CS et al (2013) Fluorescence-guided surgery of human colon cancer increases complete resection resulting in cures in an orthotopic nude mouse model. J Surg Res 179:87–93CrossRefPubMed

35.

Sexton K, Tichauer K, Samkoe KS et al (2013) Fluorescent affibody peptide penetration in glioma margin is superior to full antibody. PLoS One 8:1–9CrossRef

36.

English DP, Roque DM, Santin AD (2013) HER2 expression beyond breast cancer: therapeutic implications for gynecologic malignancies. Mol Diagn Ther 17:85–99CrossRefPubMedPubMedCentral

37.

Boonstra MC, Prakash J, Van De Velde CJH et al (2015) Stromal targets for fluorescent-guided oncologic surgery. Front Oncol 5:254CrossRefPubMedPubMedCentral

38.

van Oosten M, Crane LMA, Bart J et al (2011) Selecting potential targetable biomarkers for imaging purposes in colorectal cancer using target selection criteria (TASC): a novel target identification tool. Transl Oncol 4:71–82CrossRefPubMedPubMedCentral

39.

Hoogstins CES, Weixler B, Boogerd LSF et al (2017) In search for optimal targets for intraoperative fluorescence imaging of peritoneal metastasis from colorectal cancer. Biomark Cancer 9:1–7

40.

Weissleder R, Ntziachristos V (2003) Shedding light onto live molecular targets. Nat Med 9:123–128CrossRefPubMed

41.

Brouwer OR, Buckle T, Bunschoten A et al (2012) Image navigation as a means to expand the boundaries of fluorescence-guided surgery. Phys Med Biol 57:3123–3136CrossRefPubMed

42.

Buckle T, van Leeuwen AC, Chin PTK et al (2010) A self-assembled multimodal complex for combined pre- and intraoperative imaging of the sentinel lymph node. Nanotechnology 21:355101 (9pp)CrossRefPubMed

43.

van Leeuwen AC, Buckle T, Bendle G et al (2011) Tracer-cocktail injections for combined pre- and intraoperative multimodal imaging of lymph nodes in a spontaneous mouse prostate tumor model. J Biomed Opt. https://doi.org/10.1117/1.3528027

44.

Hekman MCH, Rijpkema M, Bos D et al (2017) Detection of micrometastases using SPECT/fluorescence dual-modality imaging in a CEA-expressing tumor model. J Nucl Med 58:706–710. https://doi.org/10.2967/jnumed.116.185470 CrossRefPubMed

Titel: Improved Debulking of Peritoneal Tumor Implants by Near-Infrared Fluorescent Nanobody Image Guidance in an Experimental Mouse Model
verfasst von: Pieterjan Debie
Marian Vanhoeij
Natalie Poortmans
Janik Puttemans
Kris Gillis
Nick Devoogdt
Tony Lahoutte
Sophie Hernot
Publikationsdatum: 01.06.2018
Verlag: Springer International Publishing
Erschienen in: Molecular Imaging and Biology / Ausgabe 3/2018
Print ISSN: 1536-1632
Elektronische ISSN: 1860-2002
DOI: https://doi.org/10.1007/s11307-017-1134-2

Neu im Fachgebiet Radiologie

18.04.2024 | Pädiatrische Notfallmedizin | Nachrichten

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Improved Debulking of Peritoneal Tumor Implants by Near-Infrared Fluorescent Nanobody Image Guidance in an Experimental Mouse Model

Abstract

Purpose

Procedures

Results

Conclusions

Neu im Fachgebiet Radiologie

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

„Nur wer sich gut aufgehoben fühlt, kann auch für Patientensicherheit sorgen“

Wie toxische Männlichkeit der Gesundheit von Männern schadet

Studie bestätigt Potenzial von KI in der Radiologie

Update Radiologie

Springer Medizin

Abstract

Purpose

Procedures

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2018

Applying Amide Proton Transfer MR Imaging to Hybrid Brain PET/MR: Concordance with Gadolinium Enhancement and Added Value to [18F]FDG PET

PET Imaging with S-[11C]Methyl-L-Cysteine and L-[Methyl-11C]Methionine in Rat Models of Glioma, Glioma Radiotherapy, and Neuroinflammation

Translating Molecular Imaging of the Vulnerable Plaque—a Vulnerable Project?

Assessing Glomerular Filtration in Small Animals Using [68Ga]DTPA and [68Ga]EDTA with PET Imaging

A Non-Peptidic S100A9 Specific Ligand for Optical Imaging of Phagocyte Activity In Vivo

Nanostructured Lipid Carrier Co-loaded with Doxorubicin and Docosahexaenoic Acid as a Theranostic Agent: Evaluation of Biodistribution and Antitumor Activity in Experimental Model

Neu im Fachgebiet Radiologie

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

„Nur wer sich gut aufgehoben fühlt, kann auch für Patientensicherheit sorgen“

Wie toxische Männlichkeit der Gesundheit von Männern schadet

Studie bestätigt Potenzial von KI in der Radiologie

Update Radiologie